HRP20161807T1 - Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže - Google Patents
Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže Download PDFInfo
- Publication number
- HRP20161807T1 HRP20161807T1 HRP20161807TT HRP20161807T HRP20161807T1 HR P20161807 T1 HRP20161807 T1 HR P20161807T1 HR P20161807T T HRP20161807T T HR P20161807TT HR P20161807 T HRP20161807 T HR P20161807T HR P20161807 T1 HRP20161807 T1 HR P20161807T1
- Authority
- HR
- Croatia
- Prior art keywords
- xten
- biologically active
- protein
- sequence
- active protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 3
- 229920001184 polypeptide Polymers 0.000 title claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 235000018102 proteins Nutrition 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 28
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000000692 natriuretic peptide Substances 0.000 claims 4
- 230000000052 comparative effect Effects 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims 2
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010011459 Exenatide Proteins 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 108010054265 Factor VIIa Proteins 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 229940012414 factor viia Drugs 0.000 claims 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
- 229960004666 glucagon Drugs 0.000 claims 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000003252 repetitive effect Effects 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14966909P | 2009-02-03 | 2009-02-03 | |
US26819309P | 2009-06-08 | 2009-06-08 | |
US18511209P | 2009-06-08 | 2009-06-08 | |
US23649309P | 2009-08-24 | 2009-08-24 | |
US23683609P | 2009-08-25 | 2009-08-25 | |
US24370709P | 2009-09-18 | 2009-09-18 | |
US24549009P | 2009-09-24 | 2009-09-24 | |
US28095609P | 2009-11-10 | 2009-11-10 | |
US28095509P | 2009-11-10 | 2009-11-10 | |
US28110909P | 2009-11-12 | 2009-11-12 | |
PCT/US2010/023106 WO2010091122A1 (en) | 2009-02-03 | 2010-02-03 | Extended recombinant polypeptides and compositions comprising same |
EP10739085.8A EP2393828B1 (en) | 2009-02-03 | 2010-02-03 | Extended recombinant polypeptides and compositions comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161807T1 true HRP20161807T1 (hr) | 2017-02-24 |
Family
ID=42542371
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161807TT HRP20161807T1 (hr) | 2009-02-03 | 2016-12-29 | Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže |
HRP20191020TT HRP20191020T1 (hr) | 2009-02-03 | 2019-06-05 | Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191020TT HRP20191020T1 (hr) | 2009-02-03 | 2019-06-05 | Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže |
Country Status (22)
Country | Link |
---|---|
US (5) | US8673860B2 (es) |
EP (3) | EP2393828B1 (es) |
JP (9) | JP5843357B2 (es) |
KR (1) | KR101544245B1 (es) |
CN (4) | CN116925238A (es) |
AU (1) | AU2010210618B2 (es) |
BR (2) | BRPI1008061B1 (es) |
CA (1) | CA2748314C (es) |
DK (2) | DK3178835T3 (es) |
EA (1) | EA020843B1 (es) |
ES (2) | ES2610356T3 (es) |
HR (2) | HRP20161807T1 (es) |
HU (1) | HUE031840T2 (es) |
IL (2) | IL213562B (es) |
LT (1) | LT2393828T (es) |
MX (2) | MX362028B (es) |
NZ (3) | NZ593833A (es) |
PL (1) | PL2393828T3 (es) |
PT (2) | PT3178835T (es) |
SI (1) | SI2393828T1 (es) |
WO (1) | WO2010091122A1 (es) |
ZA (2) | ZA201104758B (es) |
Families Citing this family (220)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2010144508A1 (en) * | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
WO2010144502A2 (en) * | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
SG181130A1 (en) | 2009-12-06 | 2012-07-30 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
EP3372617B1 (en) * | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
MY192639A (en) | 2010-07-09 | 2022-08-29 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
CN103403019B (zh) | 2010-09-28 | 2016-10-12 | 埃格里昂制药股份有限公司 | 具有增强的作用持续时间的工程化多肽 |
EP2686431B1 (en) * | 2011-03-14 | 2016-08-03 | Phlogo ApS | Antagonists of the interleukin- 1 receptor |
PT2717898T (pt) | 2011-06-10 | 2019-05-20 | Bioverativ Therapeutics Inc | Compostos pró-coagulantes e processos para a sua utilização |
MY164680A (en) | 2011-06-17 | 2018-01-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
HUE043763T2 (hu) | 2011-07-08 | 2019-09-30 | Bioverativ Therapeutics Inc | VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai |
WO2013016454A1 (en) | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
US20140323402A1 (en) * | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
JP6206972B2 (ja) * | 2011-09-12 | 2017-10-04 | アムニクス オペレーティング インコーポレイテッド | グルカゴン様ペプチド−2組成物およびその作製法および使用法 |
WO2013082200A1 (en) * | 2011-11-28 | 2013-06-06 | Shaw Gray D | Novel enhanced selectin antagonists |
SI2804623T1 (sl) | 2012-01-12 | 2020-02-28 | Bioverativ Therapeutics Inc. | Himerni polipeptidi faktorja VIII in njihove uporabe |
EA201491470A1 (ru) * | 2012-02-15 | 2015-01-30 | Амуникс Оперэйтинг Инк. | Композиции фактора viii и способы получения и использования подобных |
NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
EA037979B1 (ru) * | 2012-02-27 | 2021-06-18 | Амуникс Оперейтинг Инк. | Композиции конъюгата xten и способы их получения |
JP5967631B2 (ja) | 2012-04-27 | 2016-08-10 | 学校法人日本大学 | 上皮及び内皮損傷の治療剤 |
AU2013272220A1 (en) * | 2012-06-05 | 2015-01-15 | Amunix Operating Inc. | hGH-XTEN fusion protein and its use in the treatment of growth hormone deficiency |
NZ630849A (en) | 2012-06-08 | 2016-04-29 | Alkermes Inc | Ligands modified by circular permutation as agonists and antagonists |
CA2875246A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | キメラ性凝固因子 |
WO2014008480A2 (en) | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
RS59876B1 (sr) | 2012-07-11 | 2020-03-31 | Bioverativ Therapeutics Inc | Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena |
BR112015004734A2 (pt) * | 2012-09-07 | 2017-11-21 | Sanofi Sa | proteínas de fusão para tratar uma síndrome metabólica |
TWI810729B (zh) | 2012-09-25 | 2023-08-01 | 美商百歐維拉提夫治療公司 | Fix多肽的應用 |
WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
SG11201504558TA (en) | 2012-12-11 | 2015-07-30 | Einstein Coll Med | Methods for high throughput receptor:ligand identification |
CN102965342B (zh) * | 2012-12-12 | 2014-06-25 | 黑龙江大学 | 高效分泌表达瘦素的中国仓鼠卵巢基因工程细胞株 |
WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CA2895517C (en) | 2012-12-27 | 2022-10-11 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
MX2015012175A (es) * | 2013-03-11 | 2016-01-12 | Amunix Operating Inc | Tratamiento de la deficiencia de la hormona del crecimiento pediatrica con analogos de la hormona del crecimiento humano. |
WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
WO2014156339A1 (ja) * | 2013-03-25 | 2014-10-02 | ゼリア新薬工業株式会社 | 食後期の胃運動亢進剤 |
CN106967175A (zh) * | 2013-05-15 | 2017-07-21 | 复旦大学 | 长效干扰素及其制备方法和用途 |
WO2014190305A2 (en) | 2013-05-24 | 2014-11-27 | Biogen Idec Ma Inc. | Anti-gpiib/iiia antibodies or uses thereof |
TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合fvii-xten分子及其用途 |
KR20240023705A (ko) * | 2013-06-28 | 2024-02-22 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
WO2015021423A2 (en) | 2013-08-08 | 2015-02-12 | Biogen Idec Ma Inc. | Purification of chimeric fviii molecules |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
CA2924109A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
CN105828878A (zh) | 2013-10-28 | 2016-08-03 | 恩格姆生物制药公司 | 癌症模型及相关方法 |
US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
CA2933701C (en) | 2013-12-18 | 2022-05-31 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
HRP20240640T1 (hr) | 2014-01-10 | 2024-08-02 | Bioverativ Therapeutics Inc. | Kimerni proteini faktora viii i njihova upotreba |
AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
CN106573049A (zh) | 2014-04-21 | 2017-04-19 | Theraly制药公司 | 用于治疗纤维化疾病的trail受体激动剂 |
DK3137494T3 (da) | 2014-05-02 | 2021-10-04 | Univ New York State Res Found | Isletamyloidpolypeptider med forbedret opløselighed |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
EP3480213B1 (en) | 2014-06-18 | 2019-11-13 | Albert Einstein College of Medicine | Syntac polypeptides and uses thereof |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
TWI666319B (zh) | 2014-08-12 | 2019-07-21 | 美商巴克斯歐塔公司 | 在分泌furin之哺乳動物表現系統中生產經完全加工且具功能性之因子X |
CN105367663A (zh) * | 2014-08-31 | 2016-03-02 | 复旦大学 | 一种长效白细胞介素-1受体拮抗剂重组融合蛋白及其制备方法和用途 |
WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
CN104267194B (zh) * | 2014-09-23 | 2016-01-13 | 上海市东方医院 | 人胰高血糖素样肽-1、抗体及其试剂盒 |
TN2017000109A1 (en) | 2014-09-26 | 2018-07-04 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
DK3207130T3 (da) | 2014-10-14 | 2019-11-11 | Halozyme Inc | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme |
CA2964782A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
BR112017009951A2 (pt) * | 2014-11-11 | 2017-12-26 | Amunix Operating Inc | composições conjugadas direcionadas de xten e métodos de sua produção |
EA038349B1 (ru) | 2014-11-21 | 2021-08-12 | Бристол-Маерс Сквибб Компани | Антитела, содержащие модифицированные константные участки тяжелой цепи |
LT3221363T (lt) | 2014-11-21 | 2020-08-10 | Bristol-Myers Squibb Company | Antikūnai prieš cd73 ir jų panaudojimas |
BR112017013385A2 (pt) | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | anticorpos para tigit |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
CN106146668A (zh) * | 2015-04-01 | 2016-11-23 | 中国人民解放军第二军医大学 | 长效白细胞介素22的制备方法及其用途 |
EA035412B1 (ru) | 2015-05-29 | 2020-06-10 | Бристол-Майерс Сквибб Компани | Антитела к ox40 и их применение |
US11208452B2 (en) * | 2015-06-02 | 2021-12-28 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
UY36757A (es) | 2015-06-29 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
MX2018002226A (es) | 2015-08-28 | 2018-03-23 | Amunix Operating Inc | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo. |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
EP3359577A4 (en) * | 2015-10-08 | 2019-04-17 | The Governors of the University of Alberta | HEPATITIS C VIRUS E1 / E2 HETERODIMERS AND METHODS OF PRODUCING THE SAME |
CN105524147B (zh) * | 2015-10-15 | 2020-06-09 | 中国药科大学 | 重组聚多肽及其应用 |
KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
CA3082794A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methods for treatment of bile acid-related disorders |
EP3967707A1 (en) * | 2015-11-16 | 2022-03-16 | Ubiprotein, Corp. | A method for extending half-life of a protein |
CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
CN108474800B (zh) | 2016-01-07 | 2022-02-25 | 藤森工业株式会社 | 采血管、试剂及利用了它们的血液性状分析方法 |
EP3400020A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
IL259829B2 (en) | 2016-01-08 | 2023-03-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr–c binding |
HRP20221339T1 (hr) | 2016-01-08 | 2023-01-06 | Ascendis Pharma Growth Disorders A/S | Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida |
BR112018011152A2 (pt) | 2016-01-08 | 2018-11-21 | Ascendis Pharma Growth Disorders As | agonistas de cnp de liberação controlada com estabilidade em nep aumentada |
CA3007982C (en) | 2016-01-08 | 2023-12-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
ES2926585T3 (es) | 2016-02-01 | 2022-10-27 | Bioverativ Therapeutics Inc | Genes de Factor VIII optimizados |
AR107560A1 (es) * | 2016-02-24 | 2018-05-09 | Lilly Co Eli | Compuesto que disminuye la glucosa en la sangre |
RU2747316C2 (ru) | 2016-03-01 | 2021-05-04 | Асцендис Фарма Боун Дизизис А/С | Пролекарства pth |
MX2018008855A (es) | 2016-03-02 | 2018-11-29 | Merz Pharma Gmbh & Co Kgaa | Composicion que comprende toxina botulinica. |
BR112018067802A2 (pt) | 2016-03-04 | 2019-01-15 | Univ Rockefeller | anticorpos anti-cd40 com atividade agonista melhorada |
US20190284293A1 (en) | 2016-03-04 | 2019-09-19 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
CN109195620B (zh) | 2016-04-07 | 2022-06-28 | 约翰霍普金斯大学 | 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法 |
AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
EP3458096A4 (en) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE |
BR112018072034A2 (pt) * | 2016-05-24 | 2019-02-12 | Novo Nordisk A/S | compostos mic-1 e usos dos mesmos |
EP3463415A4 (en) | 2016-06-02 | 2020-03-25 | Indiana University Research & Technology Corporation | WATER-SOLUBLE AND CHEMICALLY STABLE GLUCAGON PEPTIDES |
EP3484523A1 (en) | 2016-07-13 | 2019-05-22 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
KR101940626B1 (ko) * | 2016-07-15 | 2019-04-10 | 한국과학기술연구원 | 반감기가 증가된 페리틴 나노케이지 및 그의 용도 |
WO2018022939A1 (en) * | 2016-07-27 | 2018-02-01 | Amunix Operating Inc. | Treatment of adult growth hormone deficiency with human growth hormone analogues |
WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
RS64177B1 (sr) | 2016-09-29 | 2023-05-31 | Ascendis Pharma Bone Diseases As | Jedinjenja pth sa niskim odnosima najviše i najniže koncentracije |
DK3518930T3 (da) | 2016-09-29 | 2023-05-01 | Ascendis Pharma Growth Disorders As | Kombinationsbehandling af en CNP-agonist med kontrolleret frigivelse |
EP3518982A1 (en) | 2016-09-29 | 2019-08-07 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
ES2959995T3 (es) | 2016-09-29 | 2024-02-29 | Ascendis Pharma Bone Diseases As | Pauta de dosificación para un compuesto de pth de liberación controlada |
CA3042512A1 (en) | 2016-11-10 | 2018-05-17 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
MA46967A (fr) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc | Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques |
CA3044838A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
MX2019009063A (es) | 2017-01-31 | 2019-10-21 | Bioverativ Therapeutics Inc | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. |
US11028137B2 (en) | 2017-02-01 | 2021-06-08 | The Research Foundation For The State University Of New York | Mutant islet amyloid polypeptides with improved solubility and methods for using the same |
SG11201908391XA (en) | 2017-03-15 | 2019-10-30 | Cue Biopharma Inc | Methods for modulating an immune response |
WO2018185131A2 (en) | 2017-04-05 | 2018-10-11 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
EA201992516A1 (ru) | 2017-04-21 | 2020-04-09 | Юхан Корпорейшн | Способ получения бифункциональных белков и их производных |
TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
EP3642222A1 (en) | 2017-06-20 | 2020-04-29 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
WO2019005623A1 (en) * | 2017-06-30 | 2019-01-03 | Adepthera Llc | PEPTIDE ANALOGS |
ES2930237T3 (es) | 2017-07-06 | 2022-12-09 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos |
US20210163986A1 (en) | 2017-08-09 | 2021-06-03 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
AU2018327224A1 (en) | 2017-09-07 | 2020-04-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
US12060424B2 (en) | 2017-12-21 | 2024-08-13 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
WO2019133747A1 (en) | 2017-12-27 | 2019-07-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
WO2019178359A1 (en) * | 2018-03-15 | 2019-09-19 | Adepthera Llc | Gel-forming polypeptides |
WO2019191295A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
CA3093083A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
MA52662A (fr) | 2018-03-28 | 2021-02-17 | Ascendis Pharma Oncology Div A/S | Conjugués d'il-2 |
MA52630A (fr) | 2018-05-18 | 2021-05-26 | Bioverativ Therapeutics Inc | Procédés de traitement de l'hémophilie a |
BR112020022306A2 (pt) | 2018-05-18 | 2021-02-23 | Ascendis Pharma Bone Diseases A/S | dose de partida de conjugados de pth |
KR20210030950A (ko) | 2018-07-03 | 2021-03-18 | 소티오, 엘엘씨 | 글루코스 이입을 향상시키는 트랜스 대사 분자와 조합된 키메라 수용체 및 이의 치료적 용도 |
PE20210632A1 (es) | 2018-07-03 | 2021-03-23 | Bristol Myers Squibb Co | Formulaciones de fgf-21 |
CN113227385A (zh) | 2018-08-09 | 2021-08-06 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
CN110964116A (zh) * | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc融合蛋白及其缀合物 |
AU2019371814A1 (en) | 2018-10-29 | 2021-06-17 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
MX2021006648A (es) | 2018-12-06 | 2021-07-07 | Bioverativ Therapeutics Inc | Uso de vectores lentivirales que expresan el factor ix. |
US12049505B2 (en) | 2018-12-06 | 2024-07-30 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
TW202039542A (zh) | 2018-12-19 | 2020-11-01 | 美商庫爾生物製藥有限公司 | 多聚體t細胞調節多肽及其使用方法 |
SG11202107446QA (en) | 2019-02-11 | 2021-08-30 | Ascendis Pharma Growth Disorders As | Dry pharmaceutical formulations of cnp conjugates |
CN113423383A (zh) | 2019-02-11 | 2021-09-21 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的液体药物制剂 |
US20220064244A1 (en) * | 2019-03-05 | 2022-03-03 | Sunshine Lake Pharma Co., Ltd. | A polypeptide molecule and application thereof |
WO2020181062A1 (en) | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
CN111718417B (zh) * | 2019-03-19 | 2022-10-14 | 宁波鲲鹏生物科技有限公司 | 含有荧光蛋白片段的融合蛋白及其用途 |
CA3143584A1 (en) | 2019-06-18 | 2020-12-24 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
US20220304993A1 (en) | 2019-06-21 | 2022-09-29 | Ascendis Pharma A/S | Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds |
EP3986477A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS |
EP3986472A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
EP4021479A2 (en) | 2019-08-27 | 2022-07-06 | Tonix Pharma Limited | Modified tff2 polypeptides |
WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
EP4058466A1 (en) | 2019-11-13 | 2022-09-21 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
US20230110994A1 (en) | 2020-01-03 | 2023-04-13 | Ascendis Pharma A/S | Conjugates undergoing intramolecular rearrangements |
WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
WO2021182928A1 (ko) | 2020-03-12 | 2021-09-16 | 주식회사 에스엘메타젠 | 신규 이중 특이성 단백질 및 그의 용도 |
TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體t細胞調節多肽及其使用方法 |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CN113820500B (zh) * | 2020-06-18 | 2023-08-11 | 中国科学院上海有机化学研究所 | 用于检测退变椎间盘微血管形成的生物标志物及其检测方法 |
KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
CN111876414A (zh) * | 2020-06-24 | 2020-11-03 | 湖南文理学院 | 一种改良酵母上游激活元件及其在鱼类中的应用 |
CA3184998A1 (en) | 2020-08-05 | 2022-02-10 | Samuel WEISBROD | Conjugates comprising reversible linkers and uses thereof |
WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
IL300668A (en) | 2020-08-28 | 2023-04-01 | Ascendis Pharma Oncology Div A/S | Glycosylated IL-2 proteins and their uses |
JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ, インコーポレイテッド | 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法 |
CA3192772A1 (en) | 2020-09-28 | 2022-03-31 | Ascendis Pharma Bone Diseases A/S | Improvement of physical and mental well-being of patients with hypoparathyroidism |
EP4222176A4 (en) | 2020-09-30 | 2024-02-28 | Beijing QL Biopharmaceutical Co., Ltd. | POLYPEPTIDE CONJUGATES AND METHODS OF USE |
TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇iv及/或viii的經生物工程改造之t細胞介導之免疫力、材料、及其他方法 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN112175964B (zh) * | 2020-10-23 | 2022-03-29 | 安徽中起生物科技有限公司 | 一种重组猪生长激素及其制备方法和应用 |
US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
EP4314035A1 (en) | 2021-04-01 | 2024-02-07 | Ascendis Pharma A/S | Use of long-acting growth hormone for treating inflammation-induced diseases |
CN113278059A (zh) * | 2021-07-14 | 2021-08-20 | 天津奇云诺德生物医学有限公司 | 一种重组人bnp蛋白及其应用 |
MX2024002333A (es) | 2021-08-23 | 2024-03-07 | Bioverativ Therapeutics Inc | Sistema de expresion de baculovirus. |
MX2024002334A (es) | 2021-08-23 | 2024-05-23 | Bioverativ Therapeutics Inc | Genes optimizados del factor viii. |
IL311712A (en) | 2021-09-27 | 2024-05-01 | Sotio Biotech Inc | Chimeric polypeptide receptors combined with trans-metabolism compounds that divert glucose metabolites outside the glycolysis pathway and their medical uses |
WO2023049926A2 (en) | 2021-09-27 | 2023-03-30 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
WO2023056331A1 (en) | 2021-09-30 | 2023-04-06 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
CN114437181B (zh) * | 2022-01-25 | 2023-03-24 | 深圳深创生物药业有限公司 | 一种glp-1r/gcgr/gipr三重受体激动剂及其应用 |
WO2023212298A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Bispecific antibodies and methods of treating ocular disease |
WO2023212294A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Angiopoietin-related protein 7-specific antibodies and uses thereof |
WO2023212293A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Complement factor h related 4-specific antibodies and uses thereof |
WO2024031034A2 (en) * | 2022-08-05 | 2024-02-08 | Staidson Biopharma Inc. | A novel il-15r alpha fc fusion protein and uses thereof |
WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
WO2024123812A1 (en) * | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
WO2024168279A2 (en) | 2023-02-10 | 2024-08-15 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same |
WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (302)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE257197C (es) | ||||
US151433A (en) * | 1874-05-26 | William f | ||
US312157A (en) * | 1885-02-10 | Fanning-mill | ||
US190740A (en) * | 1877-05-15 | Improvement in horseshoes | ||
US123997A (en) * | 1872-02-27 | Improvement in washing-machines | ||
US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4284444A (en) * | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4200984A (en) * | 1979-03-12 | 1980-05-06 | Fink Ray D | Detachable tool combining bracket and method |
US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US6692941B1 (en) | 1980-08-26 | 2004-02-17 | The Regents Of The University Of California | Bovine growth hormone |
US4398908A (en) * | 1980-11-28 | 1983-08-16 | Siposs George G | Insulin delivery system |
US4435173A (en) * | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
US4542025A (en) * | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
DE3484377D1 (de) | 1983-06-15 | 1991-05-08 | Celltech Ltd | Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien. |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
US5004804A (en) | 1984-01-12 | 1991-04-02 | Nordisk Gentofte | Method and composition for preparation of factor VIIIC |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
JPS61502760A (ja) * | 1984-07-24 | 1986-11-27 | キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド | 粘着性経皮投与層 |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
DK27885A (da) | 1985-01-22 | 1986-07-23 | Novo Industri As | Fremstilling af peptider |
US4861868A (en) | 1985-02-22 | 1989-08-29 | Monsanto Company | Production of proteins in procaryotes |
US5141922A (en) | 1985-02-22 | 1992-08-25 | Monsanto Company | Biologically active proteins and a method for their use |
EP0218712B1 (en) | 1985-04-12 | 1992-02-26 | Genetics Institute, Inc. | Novel procoagulant proteins |
US4684479A (en) * | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
EP0248819B2 (en) | 1985-09-12 | 2000-08-30 | Scios Inc. | Recombinant fibroblast growth factors |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
ATE87663T1 (de) | 1986-01-03 | 1993-04-15 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ- proteinen. |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US6759057B1 (en) * | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
US4933185A (en) * | 1986-09-24 | 1990-06-12 | Massachusetts Institute Of Technology | System for controlled release of biologically active compounds |
US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
DD257197A1 (de) | 1987-01-28 | 1988-06-08 | Univ Dresden Tech | Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4976696A (en) | 1987-08-10 | 1990-12-11 | Becton, Dickinson And Company | Syringe pump and the like for delivering medication |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
US5270176A (en) | 1987-11-20 | 1993-12-14 | Hoechst Aktiengesellschaft | Method for the selective cleavage of fusion proteins with lysostaphin |
GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5114923A (en) | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
CA1339210C (en) | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
JP2717808B2 (ja) * | 1988-08-10 | 1998-02-25 | テルモ株式会社 | シリンジポンプ |
US5089473A (en) | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
EP0394538B1 (en) | 1989-04-28 | 1996-10-16 | Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh | A yeast cell of the genus schwanniomyces |
US5017378A (en) | 1989-05-01 | 1991-05-21 | The University Of Virginia Alumni Patents Foundation | Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres |
DK0471036T4 (da) * | 1989-05-04 | 2004-07-19 | Southern Res Inst | Indkapslingsfremgangsmåde |
US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US5298022A (en) * | 1989-05-29 | 1994-03-29 | Amplifon Spa | Wearable artificial pancreas |
FR2647677B1 (fr) * | 1989-05-31 | 1991-09-27 | Roussel Uclaf | Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
US7413537B2 (en) * | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
US5631230A (en) | 1989-09-21 | 1997-05-20 | Arizona Technology Development Corporation | Receptor selective analogues of cholecystokinin-8 |
DK0556171T3 (da) | 1989-10-12 | 2000-12-18 | Univ Ohio | Væksthormon-antagonister |
US5175146A (en) | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
US5364840A (en) | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5492534A (en) | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
US5318540A (en) * | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
US5176502A (en) * | 1990-04-25 | 1993-01-05 | Becton, Dickinson And Company | Syringe pump and the like for delivering medication |
US6517859B1 (en) * | 1990-05-16 | 2003-02-11 | Southern Research Institute | Microcapsules for administration of neuroactive agents |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
CA2090969C (en) | 1990-09-04 | 2001-08-21 | Russell Arthur Brierley | Production of insulin-like growth factor-1 in methylotrophic yeast cells |
US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
SK60893A3 (en) | 1990-12-13 | 1993-10-06 | Upjohn Co | Fusion polypeptides |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US20060122376A1 (en) | 1991-02-07 | 2006-06-08 | Chiron Corporation | Protein complexes having factor VIII:C activity and production thereof |
HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
ATE198277T1 (de) | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
PT674506E (pt) | 1992-12-02 | 2001-01-31 | Alkermes Inc | Microsferas contendo hormona de crescimento com libertacao controlada |
WO1994020856A1 (en) * | 1993-03-09 | 1994-09-15 | Middlesex Sciences, Inc. | Macromolecular microparticles and methods of production |
US5981719A (en) * | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5554730A (en) * | 1993-03-09 | 1996-09-10 | Middlesex Sciences, Inc. | Method and kit for making a polysaccharide-protein conjugate |
US6090925A (en) * | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
NZ265452A (en) | 1993-03-29 | 1997-09-22 | Univ Cincinnati | Analogues of peptide yy, dimers and pharmaceutical compositions |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5576291A (en) | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
US20020042079A1 (en) * | 1994-02-01 | 2002-04-11 | Sanford M. Simon | Methods and agents for measuring and controlling multidrug resistance |
BE1008491A3 (fr) | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5739276A (en) | 1994-10-07 | 1998-04-14 | University Of Utah Research Foundation | Conotoxin peptides |
US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
US5833991A (en) | 1995-04-10 | 1998-11-10 | Cobra Therapeutics, Ltd. | Glycine-containing sequences conferring invisibility to the immune system |
US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
US5833911A (en) | 1995-05-31 | 1998-11-10 | Johnson & Johnson Medical, Inc. | Method for forming a glove using a folded glove form |
US6214797B1 (en) | 1995-06-13 | 2001-04-10 | The Salk Institute For Biological Studies | Urocortin peptides, nucleic acid encoding same methods for using same |
JPH11512087A (ja) | 1995-08-18 | 1999-10-19 | アメリカ合衆国 | ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割 |
PT1568772E (pt) | 1995-09-21 | 2010-04-14 | Genentech Inc | Variantes da hormona do crescimento humana |
US7846455B2 (en) | 1996-07-15 | 2010-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated chimeric respiratory syncytial virus |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
WO1997033552A1 (en) | 1996-03-12 | 1997-09-18 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
JP2001501173A (ja) | 1996-08-23 | 2001-01-30 | アルザ コーポレイション | シスプラチン化合物を含有するリポソーム |
WO1998016201A1 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
EP0966267B1 (en) | 1996-10-15 | 2009-02-25 | Transave, Inc. | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
ES2255103T3 (es) | 1996-10-25 | 2006-06-16 | Shire Laboratories Inc. | Sistema osmotico de administracion de dosis en forma soluble. |
US6361796B1 (en) * | 1996-10-25 | 2002-03-26 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
AU5065198A (en) | 1996-11-15 | 1998-06-10 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
EP0842657A1 (en) * | 1996-11-19 | 1998-05-20 | OctoPlus B.V. | Microspheres for controlled release and processes to prepare these microspheres |
US6395302B1 (en) * | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
AT405516B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
US20020042367A1 (en) | 1997-11-25 | 2002-04-11 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US6310183B1 (en) | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
DE69838526T2 (de) | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Gerät zum Freisetzen eines Medikaments im Herzen |
US20050260605A1 (en) * | 1998-02-11 | 2005-11-24 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
EP1054973A1 (en) | 1998-02-11 | 2000-11-29 | Maxygen, Inc. | Antigen library immunization |
US6406632B1 (en) | 1998-04-03 | 2002-06-18 | Symyx Technologies, Inc. | Rapid characterization of polymers |
US7090976B2 (en) * | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
EP1129186B2 (de) | 1998-11-10 | 2016-11-30 | Stichting Sanquin Bloedvoorziening | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
WO2000034452A1 (en) * | 1998-12-07 | 2000-06-15 | Novozymes A/S | Glucoamylases with n-terminal extensions |
US6329186B1 (en) * | 1998-12-07 | 2001-12-11 | Novozymes A/S | Glucoamylases with N-terminal extensions |
DE69934967T2 (de) | 1998-12-08 | 2007-12-06 | Biovation Ltd. | Verfahren zur verminderung der immunogenität von proteinen |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
US6713086B2 (en) * | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
EP2332603B1 (en) * | 1999-03-03 | 2013-08-14 | Optinose AS | Nasal delivery device |
US6183770B1 (en) * | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
CA2376232A1 (en) | 1999-06-14 | 2000-12-21 | Genentech, Inc. | A structured peptide scaffold for displaying turn libraries on phage |
DE60043361D1 (de) | 1999-07-23 | 2009-12-31 | Kenji Kangawa | Neue Peptide |
WO2001010892A2 (en) | 1999-08-06 | 2001-02-15 | Genentech, Inc. | Peptide antagonists of factor viia |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
US20030109428A1 (en) | 1999-12-01 | 2003-06-12 | John Bertin | Novel molecules of the card-related protein family and uses thereof |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US6352721B1 (en) * | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
PL206148B1 (pl) | 2000-02-11 | 2010-07-30 | Bayer HealthCare LLCBayer HealthCare LLC | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
JP4237375B2 (ja) | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
EP1278544A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
CA2411667A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
CA2419115C (en) | 2000-08-15 | 2011-03-08 | Board Of Trustees Of The University Of Illinois | Microparticles, and method and apparatus for forming same |
DE10053224A1 (de) * | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
US6716602B2 (en) | 2000-11-03 | 2004-04-06 | Genentech, Inc. | Metabolic rate shifts in fermentations expressing recombinant proteins |
US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US20030049689A1 (en) * | 2000-12-14 | 2003-03-13 | Cynthia Edwards | Multifunctional polypeptides |
US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
IN190699B (es) | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
IL156842A0 (en) | 2001-02-05 | 2004-02-08 | Novo Nordisk Healthcare Ag | Combined use of factor vii polypeptides and factor ix polypeptides |
PE20020908A1 (es) | 2001-03-21 | 2002-10-26 | Cell Therapeutics Inc | Produccion recombinante de polimeros polianionicos y uso de de los mismos |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US20050048512A1 (en) * | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
EP1397160A1 (en) | 2001-04-30 | 2004-03-17 | Shire Laboratories Inc. | Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
US6838093B2 (en) * | 2001-06-01 | 2005-01-04 | Shire Laboratories, Inc. | System for osmotic delivery of pharmaceutically active agents |
KR100407467B1 (ko) | 2001-07-12 | 2003-11-28 | 최수봉 | 리모컨 방식의 인슐린 자동주사기 |
US7419949B2 (en) | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
AU2002322394A1 (en) * | 2001-07-30 | 2003-02-17 | Eli Lilly And Company | Method for treating diabetes and obesity |
AU2002360264B2 (en) | 2001-10-10 | 2009-03-19 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
EP1451297A4 (en) * | 2001-12-07 | 2006-06-28 | Toolgen Inc | PHENOTYPIC SCANNING OF CHIMERIC PROTEINS |
US20080167238A1 (en) | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US7081446B2 (en) | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
SI1499888T1 (sl) | 2002-04-29 | 2010-11-30 | Euro Celtique Sa | Konformacijsko omejeni peptidi ki vežejo ORL receptor |
US6945952B2 (en) * | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
US7294513B2 (en) | 2002-07-24 | 2007-11-13 | Wyatt Technology Corporation | Method and apparatus for characterizing solutions of small particles |
US20040142870A1 (en) | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
US6965013B2 (en) | 2002-11-26 | 2005-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
WO2004055160A2 (en) | 2002-12-13 | 2004-07-01 | The Trustees Of Columbia University In The City Of New York | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
WO2004075923A2 (en) | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
TW200502222A (en) | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
US7132398B2 (en) * | 2003-05-06 | 2006-11-07 | Dendreon Corporation | Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor |
MXPA05012201A (es) | 2003-05-14 | 2006-02-10 | Dow Corning | Conjugados de agentes activos de polimero de proteina de secuencia de repeticion, metodos y usos. |
US20070161087A1 (en) | 2003-05-29 | 2007-07-12 | Wolfgang Glaesner | Glp-1 fusion proteins |
JP4644663B2 (ja) * | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
US20070203058A1 (en) | 2003-09-19 | 2007-08-30 | Novo Nordisk A/S | Novel Glp-1 Derivatives |
WO2005046583A2 (en) | 2003-10-30 | 2005-05-26 | Emory University | Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes |
EP1684790A4 (en) | 2003-11-18 | 2008-04-30 | Iconic Therapeutics Inc | HOMOGENEOUS PREPARATIONS OF CHIMERIC PROTEINS |
CN1546523A (zh) * | 2003-12-01 | 2004-11-17 | 复旦大学附属中山医院 | 一种PEG聚β肽及其制备方法 |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US20050143303A1 (en) | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
NZ548513A (en) | 2004-01-14 | 2010-05-28 | Univ Ohio | Methods of producing peptides/proteins in plants and peptides/proteins produced thereby |
KR101184391B1 (ko) * | 2004-02-09 | 2013-03-14 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
US20080233100A1 (en) | 2004-06-30 | 2008-09-25 | Yiyou Chen | Targeted enzymes |
EP3059245B1 (en) | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
CA2577999A1 (en) | 2004-08-31 | 2006-03-09 | Rory F. Finn | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
BRPI0516011A (pt) * | 2004-09-24 | 2008-08-19 | Amgen Inc | moléculas fc modificadas |
PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
EP1841787A2 (en) | 2005-01-25 | 2007-10-10 | Cell Therapeutics, Inc. | Conjugates of biologically active proteins having a modified in vivo half-life |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US20080227691A1 (en) | 2005-04-01 | 2008-09-18 | Novo Nordisk Health Care Ag | Blood Coagulation FVIII Analogues |
AU2006294644A1 (en) * | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
WO2007062270A2 (en) | 2005-11-28 | 2007-05-31 | Proteomtech Inc. | Methods for production of recombinant alpha1-antitrypsin |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
SI2402754T2 (sl) * | 2006-03-06 | 2023-09-29 | Amunix Operating Inc. | Nestrukturirani rekombinantni polimeri in njihove uporabe |
WO2007126808A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US20090169553A1 (en) | 2006-05-04 | 2009-07-02 | Molecular Innovations | Novel Protein Fusion/Tag Technology |
NZ597251A (en) | 2006-05-30 | 2013-08-30 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
JP5102833B2 (ja) | 2006-07-24 | 2012-12-19 | バイオレクシス ファーマシューティカル コーポレーション | エキセンディン融合タンパク質 |
EP2076604A4 (en) | 2006-08-31 | 2009-09-02 | Centocor Ortho Biotech Inc | GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES |
WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
PT2502938E (pt) | 2006-10-27 | 2015-06-05 | Genentech Inc | Anticorpos e imunoconjugados e suas utilizações |
CN101190945A (zh) | 2006-11-29 | 2008-06-04 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
EP2097096B1 (en) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
BRPI0720661A2 (pt) | 2006-12-27 | 2015-06-16 | Nektar Therapeutics Al Corp | Conjugados do polímero-fator de von willebrand e polímero-do fator viii tendo uma ligação liberável |
EP2099475B1 (en) | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor viia-related polypeptides |
KR101626988B1 (ko) | 2007-04-03 | 2016-06-02 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 이중특이적인 결합제들 |
CA2683423C (en) | 2007-04-26 | 2020-10-27 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
GB2467700A (en) | 2007-11-09 | 2010-08-11 | Baxter Int | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
KR20110017420A (ko) | 2008-06-04 | 2011-02-21 | 바이엘 헬스케어 엘엘씨 | 폰 빌레브란트 질환의 치료를 위한 fviii 뮤테인 |
CA2726894A1 (en) | 2008-06-27 | 2009-12-30 | Duke University | Therapeutic agents comprising elastin-like peptides |
KR20110093775A (ko) | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
WO2010144502A2 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US9849188B2 (en) * | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2010144508A1 (en) * | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
SG181130A1 (en) | 2009-12-06 | 2012-07-30 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
WO2011084808A2 (en) * | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
US20130040888A1 (en) | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
EP3372617B1 (en) * | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
WO2011136645A1 (en) | 2010-04-27 | 2011-11-03 | Stichting Katholieke Universiteit, More Particularly Radboud University Nijmegen | Fused cyclooctyne compounds and their use in metal-free click reactions |
MY192639A (en) | 2010-07-09 | 2022-08-29 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
WO2012006633A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
EP2593130A2 (en) | 2010-07-15 | 2013-05-22 | Novo Nordisk A/S | Stabilized factor viii variants |
US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
EA201491470A1 (ru) * | 2012-02-15 | 2015-01-30 | Амуникс Оперэйтинг Инк. | Композиции фактора viii и способы получения и использования подобных |
EA037979B1 (ru) * | 2012-02-27 | 2021-06-18 | Амуникс Оперейтинг Инк. | Композиции конъюгата xten и способы их получения |
AU2013272220A1 (en) | 2012-06-05 | 2015-01-15 | Amunix Operating Inc. | hGH-XTEN fusion protein and its use in the treatment of growth hormone deficiency |
RS59876B1 (sr) * | 2012-07-11 | 2020-03-31 | Bioverativ Therapeutics Inc | Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena |
WO2015021423A2 (en) * | 2013-08-08 | 2015-02-12 | Biogen Idec Ma Inc. | Purification of chimeric fviii molecules |
TWI667255B (zh) * | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
HRP20240640T1 (hr) * | 2014-01-10 | 2024-08-02 | Bioverativ Therapeutics Inc. | Kimerni proteini faktora viii i njihova upotreba |
MA40835A (fr) * | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
US9601471B2 (en) | 2015-04-23 | 2017-03-21 | Apple Inc. | Three layer stack structure |
JP6558679B2 (ja) | 2015-04-24 | 2019-08-14 | パナソニックIpマネジメント株式会社 | 点灯装置、照明装置及び照明器具 |
AU2016301303B2 (en) * | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
AR107560A1 (es) * | 2016-02-24 | 2018-05-09 | Lilly Co Eli | Compuesto que disminuye la glucosa en la sangre |
-
2010
- 2010-02-03 MX MX2015001906A patent/MX362028B/es unknown
- 2010-02-03 KR KR1020117020195A patent/KR101544245B1/ko active IP Right Grant
- 2010-02-03 HU HUE10739085A patent/HUE031840T2/en unknown
- 2010-02-03 EA EA201170993A patent/EA020843B1/ru not_active IP Right Cessation
- 2010-02-03 LT LTEP10739085.8T patent/LT2393828T/lt unknown
- 2010-02-03 CA CA2748314A patent/CA2748314C/en active Active
- 2010-02-03 CN CN202310784571.8A patent/CN116925238A/zh active Pending
- 2010-02-03 EP EP10739085.8A patent/EP2393828B1/en active Active
- 2010-02-03 WO PCT/US2010/023106 patent/WO2010091122A1/en active Application Filing
- 2010-02-03 PT PT16189957T patent/PT3178835T/pt unknown
- 2010-02-03 SI SI201031362A patent/SI2393828T1/sl unknown
- 2010-02-03 PT PT107390858T patent/PT2393828T/pt unknown
- 2010-02-03 NZ NZ593833A patent/NZ593833A/xx unknown
- 2010-02-03 US US12/699,761 patent/US8673860B2/en active Active
- 2010-02-03 NZ NZ628987A patent/NZ628987A/en unknown
- 2010-02-03 BR BRPI1008061-9A patent/BRPI1008061B1/pt active IP Right Grant
- 2010-02-03 CN CN201080011467.6A patent/CN102348715B/zh active Active
- 2010-02-03 DK DK16189957.0T patent/DK3178835T3/da active
- 2010-02-03 ES ES10739085.8T patent/ES2610356T3/es active Active
- 2010-02-03 JP JP2011548425A patent/JP5843357B2/ja active Active
- 2010-02-03 EP EP16189957.0A patent/EP3178835B1/en active Active
- 2010-02-03 CN CN202211696300.9A patent/CN117050147A/zh active Pending
- 2010-02-03 PL PL10739085T patent/PL2393828T3/pl unknown
- 2010-02-03 DK DK10739085.8T patent/DK2393828T3/da active
- 2010-02-03 BR BR122021021381-0A patent/BR122021021381B1/pt active IP Right Grant
- 2010-02-03 EP EP19159177.5A patent/EP3581579A1/en active Pending
- 2010-02-03 MX MX2011008094A patent/MX2011008094A/es active IP Right Grant
- 2010-02-03 AU AU2010210618A patent/AU2010210618B2/en active Active
- 2010-02-03 CN CN201810002126.0A patent/CN108530543B/zh active Active
- 2010-02-03 NZ NZ606427A patent/NZ606427A/en unknown
- 2010-02-03 ES ES16189957T patent/ES2730800T3/es active Active
-
2011
- 2011-06-14 IL IL213562A patent/IL213562B/en active IP Right Grant
- 2011-06-27 ZA ZA2011/04758A patent/ZA201104758B/en unknown
-
2014
- 2014-01-30 US US14/168,973 patent/US9371369B2/en active Active
- 2014-09-22 JP JP2014192566A patent/JP6012684B2/ja active Active
- 2014-10-22 ZA ZA2014/07665A patent/ZA201407665B/en unknown
-
2016
- 2016-03-07 JP JP2016043162A patent/JP6265564B2/ja active Active
- 2016-05-13 US US15/154,223 patent/US9926351B2/en active Active
- 2016-06-02 IL IL245994A patent/IL245994A0/en active IP Right Grant
- 2016-11-04 JP JP2016215924A patent/JP6348946B2/ja active Active
- 2016-12-29 HR HRP20161807TT patent/HRP20161807T1/hr unknown
-
2018
- 2018-02-02 US US15/887,313 patent/US10961287B2/en active Active
- 2018-02-02 JP JP2018017361A patent/JP2018076378A/ja not_active Withdrawn
-
2019
- 2019-06-05 HR HRP20191020TT patent/HRP20191020T1/hr unknown
- 2019-08-14 JP JP2019148734A patent/JP2019213548A/ja not_active Withdrawn
-
2021
- 2021-01-07 JP JP2021001297A patent/JP2021059595A/ja not_active Withdrawn
- 2021-01-15 US US17/150,426 patent/US12071456B2/en active Active
-
2022
- 2022-10-21 JP JP2022169283A patent/JP7461438B2/ja active Active
-
2024
- 2024-03-22 JP JP2024046347A patent/JP2024081707A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161807T1 (hr) | Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže | |
AU2017261216B2 (en) | ELP fusion proteins for controlled and sustained release | |
Lee et al. | Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1 | |
US7960336B2 (en) | Composition for long-acting peptide analogs | |
HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
CN105324397A (zh) | 胰岛素-肠促胰岛素缀合物 | |
JP2018515088A5 (es) | ||
RU2010103995A (ru) | Бифункциональные слитые белки альфа-меланоцитостимулирующего гормона (альф-msh) и атриального натрийуретического белка (anp) и их применение при гипертонии и остром повреждении почек | |
PE20090311A1 (es) | Proteinas de fusion natriureticas | |
JP2009525052A5 (es) | ||
PE20090932A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 | |
JP2010536341A5 (es) | ||
CA2880929A1 (en) | Fusion proteins for treating a metabolic syndrome | |
ATE517119T1 (de) | Einzelketteninsulin | |
KR20140103985A (ko) | 인슐린 아미노산 서열을 포함하는 치료제 | |
HRP20240640T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
HRP20100644T1 (hr) | Cijepivo kombinacije peptida protiv alergije na macke | |
CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
RU2016124562A (ru) | Фармацевтическая композиция для лечения метаболического синдрома | |
KR20130018965A (ko) | 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드 | |
AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
HRP20210635T1 (hr) | Novi mutant humanog seruma albumina | |
RU2016123180A (ru) | Миметика кальцитонина для лечения болезней и нарушений | |
CA2890719A1 (en) | Long-acting single-chain insulin analogues | |
US20200079833A1 (en) | Protease-resistant lipidated glp-1 analogs |